GridAI Technologies Corp

GridAI Technologies Corp. is a diversified technology and life sciences company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 2 full-time employees. The company went IPO on 2016-10-11. The company applies real-time AI scheduling and optimization to orchestrate devices, fleets, and grid-scale assets. The firm also focuses on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The firm's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.